The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed. 

The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.

These new findings challenge the long-standing assumption that low levels of alcohol do not meaningfully influence a person's blood pressure.

Researchers tracked patients for two years, using echocardiography to confirm the devices had completely vanished. Additional studies will still be required.

The 2025 HLTH convention in Las Vegas, held at the Venetian Expo Center, brought together vendors, researchers and healthcare providers for four days of presentations, panels, awards and industry announcements. Here's a selection of news from the show floor.